Literature DB >> 11568058

Intracoronary infusion of skeletal myoblasts improves cardiac function in doxorubicin-induced heart failure.

K Suzuki1, B Murtuza, N Suzuki, R T Smolenski, M H Yacoub.   

Abstract

BACKGROUND: Skeletal myoblast transplantation is promising for the treatment of end-stage heart failure. Direct intramyocardial injection is useful for local cell delivery but may not be effective in global dissemination of cells into the heart, which would be advantageous in treating generalized cardiac dysfunction as in dilated cardiomyopathy. We hypothesized that intracoronary infusion of myoblasts would disseminate cells more effectively, leading to functional improvement in global heart failure. METHODS AND
RESULTS: Heart failure was induced by the intraperitoneal administration of doxorubicin (total dose 15 mg/kg) in rat. One million primary skeletal myoblasts were then infused via the coronary arteries of an excised, failing doxorubicin-treated heart. After incubation under increased intracoronary pressure, the hearts were subsequently transplanted into syngeneic recipients. For the control group, doxorubicin-treated hearts were infused with medium only and transplanted. Four weeks after transplantation, Langendorff perfusion demonstrated that both maximum dP/dt (2797.6+/-103.3 versus 2326.9+/-133.1 mm Hg/s, P=0.01) and minimum dP/dt (-2067.4+/-88.1 versus -1718.8+/-91.3 mm Hg/s, P=0.02) were improved in myoblast-transplanted hearts compared with medium-infused hearts. This was associated with a sharper slope of the left ventricular developed pressure-volume curve and a reduced slope of the end-diastolic pressure-volume relation in the myoblast-transplanted hearts. Immunohistochemistry for skeletal myosin heavy chain showed that globally disseminated myoblasts had survived and differentiated into multinucleated myotubes that had aligned with the cardiac fiber axis within host myocardium. No significant myocardial infarction was observed.
CONCLUSIONS: We demonstrated the feasibility and efficiency of skeletal myoblast transplantation via the intracoronary route as a promising strategy for improving cardiac function in global heart failure.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11568058     DOI: 10.1161/hc37t1.094929

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

Review 1.  Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions.

Authors:  Santosh K Sanganalmath; Roberto Bolli
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

2.  Myoblasts and embryonic stem cells differentially engraft in a mouse model of genetic dilated cardiomyopathy.

Authors:  Cyril Catelain; Stéphanie Riveron; Aurélie Papadopoulos; Nathalie Mougenot; Adeline Jacquet; Karine Vauchez; Erica Yada; Michel Pucéat; Marc Fiszman; Gillian Butler-Browne; Gisèle Bonne; Jean-Thomas Vilquin
Journal:  Mol Ther       Date:  2013-02-26       Impact factor: 11.454

3.  Granulocyte-colony stimulating factor enhanced the recruitment of bone marrow cells into the heart: time course evaluation of phenotypic differentiation in the doxorubicin-induced cardiomyopathic model.

Authors:  Yosuke Hisashi; Shinji Tomita; Takeshi Nakatani; Shinya Fukuhara; Chikao Yutani; Soichiro Kitamura
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2004-10

4.  Anthracycline cardiotoxicity: from bench to bedside.

Authors:  Luca Gianni; Eugene H Herman; Steven E Lipshultz; Giorgio Minotti; Narine Sarvazyan; Douglas B Sawyer
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

5.  MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases.

Authors:  Husnain Kh Haider; Ye Lei; Muhammad Ashraf
Journal:  Curr Opin Mol Ther       Date:  2008-12

Review 6.  Mesenchymal stem cell: present challenges and prospective cellular cardiomyoplasty approaches for myocardial regeneration.

Authors:  Debayon Paul; Samson Mathews Samuel; Nilanjana Maulik
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

7.  Cellular retrograde cardiomyoplasty and relaxin therapy for postischemic myocardial repair in a rat model.

Authors:  Gabriella Di Lascio; Guy Harmelin; Mattia Targetti; Cristina Nanni; Giacomo Bianchi; Tommaso Gasbarri; Sandro Gelsomino; Daniele Bani; Sandra Zecchi Orlandini; Massimo Bonacchi
Journal:  Tex Heart Inst J       Date:  2012

Review 8.  The current status and future of cardiac stem/progenitor cell therapy for congenital heart defects from diabetic pregnancy.

Authors:  Jianxiang Zhong; Shengbing Wang; Wei-Bin Shen; Sunjay Kaushal; Peixin Yang
Journal:  Pediatr Res       Date:  2017-11-15       Impact factor: 3.756

Review 9.  Endometrial regenerative cells for treatment of heart failure: a new stem cell enters the clinic.

Authors:  Leo Bockeria; Vladimir Bogin; Olga Bockeria; Tatyana Le; Bagrat Alekyan; Erik J Woods; Amalia A Brown; Thomas E Ichim; Amit N Patel
Journal:  J Transl Med       Date:  2013-03-05       Impact factor: 5.531

10.  QiShenYiQi Pills, a Compound Chinese Medicine, Ameliorates Doxorubicin-Induced Myocardial Structure Damage and Cardiac Dysfunction in Rats.

Authors:  Dong-Xin Tang; Hai-Ping Zhao; Chun-Shui Pan; Yu-Ying Liu; Xiao-Hong Wei; Xiao-Yuan Yang; Yuan-Yuan Chen; Jing-Yu Fan; Chuan-She Wang; Jing-Yan Han; Ping-Ping Li
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-26       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.